Evotec wins grant to take H3 receptor antagonist drug into clinical
3 June 2010
Hamburg-based Evotec AG has won funding of up to
€1.5 million from the German Federal
Ministry of Education and Research (BMBF) to advance its H3 receptor
antagonist drug programme into clinical trials.
Using its central nervous system (CNS) expertise coupled with its
world leading discovery platform Evotec has successfully identified
and optimised H3 receptor antagonists through to preclinical
development. This grant will now provide external funding for Evotec
to advance the programme through Phase I clinical studies.
The histamine H3 receptor is a drug target of high interest
because of evidence that blocking this receptor in the brain can
improve cognition, alertness and attention. H3 receptor antagonists
therefore have the potential to become an important new class of
therapy in a number of CNS indications, including excessive fatigue
associated with conditions such as multiple sclerosis.
Dr Werner Lanthaler, Chief Executive Officer of Evotec commented:
“We are happy that the Neu² consortium has chosen to support our H3
receptor antagonist programme for further development within the
BioPharma initiative. By driving these novel drug candidates from
identification through to the first clinical steps, we can optimally
capture the commercial value of this programme.”